MedTrace Logo

Evaluation of Efficacy and Tolerability of Hizentra®

NCT01354587 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-07-17

No results posted yet for this study

Summary

The purpose of this study is to measure the changes in the Treatment Satisfaction Questionnaire for Medication in the areas of effectiveness, side effects, and convenience of administration of each medication in Primary Immunodeficiency Disorder (PIDD) subjects transitioning from subcutaneous Vivaglobin® to Hizentra®.

Conditions

  • Primary Immunodeficiency Disorders

Interventions

DRUG

Hizentra

Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.

Sponsors & Collaborators

  • University of South Florida

    lead OTHER

Principal Investigators

  • John Sleasman, MD · University of South Florida

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354587 on ClinicalTrials.gov